Abstract
24 Background: Aspirin use has been associated with a decreased incidence and mortality of various gastrointestinal malignancies. In this study, we evaluated the association between aspirin use and gastric cancer risk. Methods: We randomly selected 200,000 patients with hypertension or type 2 diabetes from the Korean National Health Insurance claim database at 2004. Of these, 3,907 patients who used aspirin regularly (aspirin users) and 7,808 patients who did not use aspirin (aspirin non-users) were selected by 1:2 frequency matching (age, sex, co-morbid illnesses, and starting time of follow-up), and assessed gastric cancer incidence during the followed-up periods from January 2004 to December 2010. Results: In the matched cohort, the incidence rates of gastric cancer were 0.8% (31/3,907) in aspirin users and 1.1% (86/7,808) in aspirin non-users, but the cumulative incidence rates were not significantly different between aspirin users and non-users (P=0.11, log-rank test). Although there was no statistical significance, a multivariate analysis showed that aspirin use was associated with reduced gastric cancer risk (adjusted hazard ratio [AHR], 0.71; 95% confidential interval [CI], 0.47–1.08; P=0.11). However, duration of aspirin use was significantly associated with the reduction of gastric cancer risk (overall AHR, 0.85; 95% CI 0.73–1.00, P=0.04), especially in patients that used aspirin for more than 3 years (AHR, 0.40; 95% CI, 0.16–0.98; P=0.04). Conclusions: Long-term regular aspiri n use is significantly associated with reduced gastric cancer risk.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call